Candel Therapeutics, Inc. (CADL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CADL currently has 73.3M outstanding shares. with moderate dilution risk from 17.1M authorized shares representing 23.3% potential dilution. The company has significantly diluted shareholders by 112.45% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 73.3M shares outstanding |
73M | 17M |
| Mar 12, 2026 |
10-K filing | 73.2M shares outstanding |
73M | 17M |
| Oct 14, 2025 |
8-K filing: Candel Therapeutics, Inc. entered into a Loan and Security Agreement for up to $130.0 million and issued warrants to the lenders to purchase shares of common stock. |
51M | 17M |
| Aug 14, 2025 |
S-3 filing: The filing is an S-3 registration statement for a shelf offering of common stock, preferred stock, and debt securities. The company may issue up to $300,000,000 in aggregate principal amount of its securities. The offering includes an at-the-market offering of common stock with an aggregate offering price of up to $50,000,000 through Jefferies LLC. |
55M | 17M |
| Aug 14, 2025 |
10-Q filing | 51.5M shares outstanding |
51M | 17M |
| May 13, 2025 |
10-Q filing | 50.5M shares outstanding |
50M | 17M |
| Mar 13, 2025 |
10-K filing | 47.2M shares outstanding |
47M | 17M |
| Nov 14, 2024 |
10-Q filing | 32.0M shares outstanding |
32M | 17M |
| Aug 13, 2024 |
10-Q filing | 29.9M shares outstanding |
30M | 17M |
| May 14, 2024 |
10-Q filing | 29.2M shares outstanding |
29M | 17M |
| Mar 28, 2024 |
10-K filing | 28.9M shares outstanding |
29M | 17M |
| Nov 09, 2023 |
10-Q filing | 28.9M shares outstanding |
29M | 17M |
| Aug 10, 2023 |
10-Q filing | 28.9M shares outstanding |
29M | 17M |
| May 11, 2023 |
10-Q filing | 28.9M shares outstanding |
29M | 17M |
| Mar 30, 2023 |
10-K filing | 28.8M shares outstanding |
29M | 17M |
| Nov 10, 2022 |
10-Q filing | 28.9M shares outstanding |
29M | 17M |
| Aug 05, 2022 |
10-Q filing | 28.8M shares outstanding |
29M | 17M |
| Aug 05, 2022 |
S-3 filing: Candel Therapeutics files an S-3 for a mixed shelf offering of up to $200,000,000 in common stock, preferred stock, debt securities, warrants and/or units and also files for an offering up to $75,000,000 in aggregate amount of common stock from time to time through Jefferies, acting as its sales agent. |
29M | 17M |
| May 12, 2022 |
10-Q filing | 28.7M shares outstanding |
29M | 17M |
| Mar 29, 2022 |
10-K filing | 28.7M shares outstanding |
29M | 17M |
| Nov 12, 2021 |
10-Q filing | 28.7M shares outstanding |
29M | 17M |
| Sep 08, 2021 |
10-Q filing | 28.7M shares outstanding |
29M | 17M |
| Jul 26, 2021 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. The company is offering 9,000,000 shares of common stock (or 10,350,000 shares if the underwriters exercise their option to purchase additional shares in full) at an initial public offering price of $8.00 per share. |
28M | 17M |
| Jul 16, 2021 |
S-1/A filing: S-1/A filing for common stock offering. |
19M | 6.2M |
| Jun 25, 2021 |
S-1 filing: This S-1 filing details a proposed offering of common stock, with an option for underwriters to purchase additional shares, to fund clinical trials, manufacturing, and general corporate purposes. It also discusses the pro forma net loss per share and weighted-average shares of common stock outstanding. |
N/A | 0 |